Research ArticleMalaria

Prime and target immunization protects against liver-stage malaria in mice

See allHide authors and affiliations

Science Translational Medicine  26 Sep 2018:
Vol. 10, Issue 460, eaap9128
DOI: 10.1126/scitranslmed.aap9128

A malaria vaccine to harness hepatic immunity

Plasmodium, the parasitic agent of malaria, has a fairly complicated life cycle in different organs of the host. Malaria vaccines can be designed to disrupt a particular parasitic stage. Gola et al. are interested in developing a malaria vaccine that protects against liver-stage malaria. To do so, they used nanoparticles or viral vectors. The vaccines induced tissue-resident memory CD8+ T cells in mice, which conferred sterilizing protection against sporozoite challenge. One of the viral vector vaccine candidates was tested in healthy human volunteers and was found to be safe. The investigators are hopeful that this vaccine can induce protective liver-resident T cells in humans.

View Full Text

Stay Connected to Science Translational Medicine